You need to create a user account to read this article.
With a subscription you unlock more content on BioStock.
Sobi has entered into a new agreement with Apellis Pharmaceuticals to reduce its royalty obligations for Aspaveli outside the US. The deal includes an upfront payment of USD 275 million and potential milestone payments of...